Eli Lilly Acquires AtaiBeckley for $2.8 Billion Plus Contingent Value Rights

Eli Lilly and Company has entered into a definitive agreement to acquire AtaiBeckley, a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions. Under the terms, Lilly will pay $6.75 per share in cash plus up to $2.50 per share in contingent value rights tied to development and regulatory milestones for BPL-003 and VLS-01, with the deal expected to close in the third quarter subject to customary approvals. A later update indicates Lilly has completed the acquisition following AtaiBeckley shareholder approval, integrating the clinical-stage pipeline into Lilly’s neuroscience R&D organization.